Galectin Therapeutics (GALT) Accumulated Expenses (2010 - 2026)
Galectin Therapeutics' quarterly Accumulated Expenses came in at $4.2 million in Q1 2026, up 665.27% year-on-year from $547000.0 in Q1 2025, and down 11.35% quarter-over-quarter from $4.7 million in Q4 2025.
Galectin Therapeutics has reported Accumulated Expenses for 17 years, with the latest figure at $4.2 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 665.27% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 665.27% YoY), and the FY2025 full-year result was $4.7 million, down 42.44% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $4.2 million, down from $4.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $10.9 million in Q2 2024, with the low at $300000.0 in Q1 2022.
- Average Accumulated Expenses over 5 years is $4.1 million, with a median of $1.1 million recorded in 2023.
- Year-over-year, Accumulated Expenses soared 2893.33% in 2023 and slumped 93.81% in 2025.
- Tracing GALT's Accumulated Expenses over 5 years: stood at $9.1 million in 2022, then tumbled by 87.54% to $1.1 million in 2023, then jumped by 626.66% to $8.2 million in 2024, then sank by 42.44% to $4.7 million in 2025, then fell by 11.35% to $4.2 million in 2026.
- The last three Accumulated Expenses figures came in at $4.2 million (Q1 2026), $4.7 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.19 Mn |
| Dec 31, 2025 | 4.72 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 6.90 Mn |
| Dec 31, 2024 | 8.20 Mn |
| Sep 30, 2024 | 11.59 Mn |
| Jun 30, 2024 | 10.86 Mn |
| Mar 31, 2024 | 8.84 Mn |
| Dec 31, 2023 | 1.13 Mn |
| Sep 30, 2023 | 7.84 Mn |
| Jun 30, 2023 | 641,000.00 |
| Mar 31, 2023 | 8.98 Mn |
| Dec 31, 2022 | 973,000.00 |
| Sep 30, 2022 | 7.24 Mn |
| Jun 30, 2022 | 7.86 Mn |
| Mar 31, 2022 | 300,000.00 |
| Dec 31, 2021 | 7.16 Mn |
| Sep 30, 2021 | 520,000.00 |
| Jun 30, 2021 | 5.07 Mn |
| Mar 31, 2021 | 4.28 Mn |
| Dec 31, 2020 | 789,000.00 |
| Sep 30, 2020 | 1.80 Mn |
| Jun 30, 2020 | 4.00 Mn |
| Mar 31, 2020 | 656,000.00 |
| Dec 31, 2019 | 1.09 Mn |
| Sep 30, 2019 | 862,000.00 |
| Jun 30, 2019 | 857,000.00 |
| Mar 31, 2019 | 459,000.00 |
| Dec 31, 2018 | 1.51 Mn |
| Sep 30, 2018 | 1.01 Mn |
| Jun 30, 2018 | 1.15 Mn |
| Mar 31, 2018 | 314,000.00 |
| Dec 31, 2017 | 2.29 Mn |
| Sep 30, 2017 | 361,000.00 |
| Jun 30, 2017 | 3.05 Mn |
| Mar 31, 2017 | 3.02 Mn |
| Dec 31, 2016 | 614,000.00 |
| Sep 30, 2016 | 3.44 Mn |
| Jun 30, 2016 | 2.64 Mn |
| Mar 31, 2016 | 439,000.00 |
| Dec 31, 2015 | 626,000.00 |
| Sep 30, 2015 | 485,000.00 |
| Jun 30, 2015 | 1.07 Mn |
| Mar 31, 2015 | 214,000.00 |
| Dec 31, 2014 | 729,000.00 |
| Sep 30, 2014 | 542,000.00 |
| Jun 30, 2014 | 310,000.00 |
| Mar 31, 2014 | 1.45 Mn |
| Dec 31, 2013 | 526,000.00 |
| Sep 30, 2013 | 57,000.00 |
| Jun 30, 2013 | 36,000.00 |
| Mar 31, 2013 | 61,000.00 |
| Dec 31, 2012 | 42,000.00 |
| Sep 30, 2012 | 1.19 Mn |
| Jun 30, 2012 | 1.25 Mn |
| Mar 31, 2012 | 1.27 Mn |
| Dec 31, 2011 | 1.55 Mn |
| Sep 30, 2011 | 417,000.00 |
| Jun 30, 2011 | 376,000.00 |
| Dec 31, 2010 | 537,000.00 |